Compare Tapestry, Inc. (TPR) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tapestry, Inc. vs Twist Bioscience Corp — how do they compare? Tapestry, Inc. trades at $116.24 (market cap $23.09B), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: Tapestry, Inc. is far larger — about 2.3× Twist Bioscience Corp's market cap, and Tapestry, Inc. pays a 1.6% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tapestry, Inc. for 70 Days and Twist Bioscience Corp for 27 Days on average.
| TPR | TWST | |
|---|---|---|
Market Cap | $23.09B | $10.08B |
Volume | 2,745,259 | 4,229,037 |
Sector | Consumer Cyclical | Health |
52-Week High | $164.78 | $205.00 |
52-Week Low | $98.81 | $25.45 |
Typical Hold Time | 70 Days | 27 Days |
Enterprise Value | $25.89B | $10.01B |
Dividend Yield | 1.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TPR trades at $115.82, up 2.14% today, with strong analyst support (73% buy ratings) and a $174.64 consensus price target suggesting 51% upside. The stock shows robust profitability with 77.82% gross margins and has beaten earnings estimates for three consecutive quarters. However, technical indicators signal bearish momentum, and 2025 net income declined significantly to $183M from prior years above $800M. Recent news highlights Coach's momentum and international growth in China and Europe.
The investment case balances strong brand performance and analyst optimism against execution risks and valuation concerns. Upside potential exists from earnings beats and international expansion, but investors face headwinds from Kate Spade performance issues, tariff pressures, and the stock's current bearish technical trend. The significant gap between current price and analyst targets presents opportunity if fundamental improvements materialize.
Twist Bioscience (TWST) trades at $152.05, down 2.31% today but remains near recent highs following a significant rally driven by AI partnerships and strong sector interest. The company shows improving revenue growth ($377M in 2025) but continues to post substantial losses (-$78M net income). Technical indicators show mixed signals with bullish overall sentiment but bearish moving averages, while analyst consensus remains positive with 73% buy ratings.
TWST presents a high-risk, high-reward opportunity with strong growth potential through AI-driven drug discovery partnerships but faces significant execution risks amid persistent profitability challenges. The stock's valuation appears stretched given current fundamentals, requiring successful commercialization of pipeline assets to justify premium multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
